Literature DB >> 11777210

Paired tumor marker of soluble E-selectin and its ligand sialyl Lewis A in colorectal cancer.

K Ito1, C L Ye, K Hibi, C Mitsuoka, R Kannagi, K Hidemura, H Ando, Y Kasai, S Akiyama, A Nakao.   

Abstract

BACKGROUND: Better diagnosis of metastatic disease has been pursued by oncologists: however, many of the tumor markers have been still controversial. Our purpose was to estimate the usefulness of soluble E-selectin and its ligand sialyl Lewis A for more accurate diagnosis as a combined tumor marker for metastases in colorectal cancer.
METHODS: E-selectin and sialyl Lewis A, collected from preoperative blood, were measured of its levels in 54 patients with colorectal cancer classified according to Dukes' stage. E-selectin was assayed by enzyme-linked immunosorbent assay, whereas sialyl Lewis A was quantified by enzyme immunoassay using immunoclone kit.
RESULTS: The elevation in the level of E-selectin was significantly higher in Dukes' D group than that of healthy volunteers (P < 0.001, Fisher's procedure of least significance test), Dukes' A (P = 0.01), B (P = 0.025) and C (P < 0.01). Significantly higher level of sialyl Lewis A was shown in the group of metastases than that of non-metastases (P < 0.0068. Student's t-test). Paired elevation of E-selectin and sialyl Lewis A was significantly higher in the hematogenous metastases than non-metastases (P < 0.001, Fisher exact test).
CONCLUSIONS: These results suggest that E-selectin could play some role in the progress of hematogenous metastases. The elevation of E-selectin alone or both E-selectin and sialyl Lewis A may be one of the useful indexes for more precise diagnosis of hematogenous metastases of human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11777210     DOI: 10.1007/s005350170004

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  8 in total

1.  Development of a microplate ELISA for circulating E-selectin: assay characterization, comparison with a commercial kit, wand establishment of normal reference values.

Authors:  Kuo-Chien Tsao; Pi-Yueh Chang; Chia-Chi Li; Tsu-Lan Wu; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

Review 2.  Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis.

Authors:  Stéphanie Gout; Pierre-Luc Tremblay; Jacques Huot
Journal:  Clin Exp Metastasis       Date:  2007-09-21       Impact factor: 5.150

Review 3.  Targeting selectins and selectin ligands in inflammation and cancer.

Authors:  Steven R Barthel; Jacyln D Gavino; Leyla Descheny; Charles J Dimitroff
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

Review 4.  Biological modulation by lectins and their ligands in tumor progression and metastasis.

Authors:  Susumu Nakahara; Avraham Raz
Journal:  Anticancer Agents Med Chem       Date:  2008-01       Impact factor: 2.505

5.  Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.

Authors:  Mevlüde Inanç; Ozlem Er; Halit Karaca; Veli Berk; Metin Ozkan; Recep Saraymen; Ferhan Elmalı
Journal:  Med Oncol       Date:  2012-05-12       Impact factor: 3.064

6.  C2-O-sLeX glycoproteins are E-selectin ligands that regulate invasion of human colon and hepatic carcinoma cells.

Authors:  Catherine A St Hill; Dahabo Baharo-Hassan; Mariya Farooqui
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

Review 7.  The engagement of selectins and their ligands in colorectal cancer liver metastases.

Authors:  Konstantinos A Paschos; David Canovas; Nigel C Bird
Journal:  J Cell Mol Med       Date:  2010-01       Impact factor: 5.310

Review 8.  Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology.

Authors:  Elisabete Fernandes; Janine Sores; Sofia Cotton; Andreia Peixoto; Dylan Ferreira; Rui Freitas; Celso A Reis; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Theranostics       Date:  2020-03-31       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.